Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketdailypress.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketDailyPress.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent BIIB Stock Price: $265.17
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Andrew Fein analyst at H.C. Wainwright reiterates coverage on Biogen (BIIB) stock in the energy sector with a Buy rating and has set BIIB's stock price target at $ 325.
TipRanks.com reports that Biogen currently has 20 analysts offering 12-month price targets on BIIB and the consensus is a Strong Buy rating with an average stock price target of $330.94. The most recent BIIB stock price we have is $265.17 and we are not making any BIIB forecasts at this time.
In addition, TradingView issued a Sell rating for BIIB over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIIB, please click here >>
Karuna Therapeutics, KRTX
Recent KRTX Stock Price: $176.22
Summary: Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute psychosis in patients with schizophrenia, which are in clinical stage. Karuna Therapeutics Inc. is based in Boston, Massachusetts.
Caroline Palomeque analyst at Berenberg Bank reiterates coverage on Karuna Therapeutics (KRTX) stock in the energy sector with a Buy rating and has set KRTX's stock price target at $ 282.
TipRanks.com reports that Karuna Therapeutics currently has 16 analysts offering 12-month price targets on KRTX and the consensus is a Strong Buy rating with an average stock price target of $274.13. The most recent KRTX stock price we have is $176.22 and we are not making any KRTX forecasts at this time.
In addition, TradingView issued a Sell rating for KRTX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRTX. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on KRTX, please click here >>
Recent ETNB Stock Price: $16.94
Summary: 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.
Ed Arce analyst at H.C. Wainwright reiterates coverage on 89bio (ETNB) stock in the energy sector with a Buy rating and has set ETNB's stock price target at $ 30.
TipRanks.com reports that 89bio currently has 8 analysts offering 12-month price targets on ETNB and the consensus is a Strong Buy rating with an average stock price target of $33.75. The most recent ETNB stock price we have is $16.94 and we are not making any ETNB forecasts at this time.
In addition, TradingView issued a Strong Buy rating for ETNB over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ETNB. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ETNB, please click here >>
The editors at marketdailypress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketDailyPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketDailyPress.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.